Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

November 6th 2020

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

Dr. Srinivasan on the Challenges of Developing New Therapies in Rare RCC Subtypes

November 4th 2020

Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.

KidneyCAN 2020 Touts Power of Translational Research in Advancing RCC Field

November 3rd 2020

The 2020 Kidney Cancer Research Summit (KidneyCAN) featured several healthcare experts who highlighted the latest clinical developments, critical preclinical efforts, and translational research being performed to move the needle forward in the field of kidney cancer.

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

October 30th 2020

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

October 28th 2020

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC

October 28th 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Approval Sought for Cabozantinib/Nivolumab for Unresectable, Advanced, or Metastatic RCC in Japan

October 27th 2020

A supplemental application was submitted to the Japanese Ministry of Health, Labour, and Welfare for Manufacturing and Marketing approval of the combination of cabozantinib plus nivolumab for the treatment of patients with unresectable, advanced, or metastatic renal cell carcinoma.

Panelists Stress Importance of Putting Your Best Foot Forward in Advanced RCC

October 23rd 2020

Kidney cancer experts emphasize the importance of risk stratification for guiding treatment decisions and discussed the clinical trials that have shaped the frontline treatment recommendations from the National Comprehensive Cancer Network for advanced clear cell RCC.

Final Thoughts on the Management of mRCC

October 23rd 2020

Additional Emerging Therapies for Progressive mRCC

October 23rd 2020

Emerging Agents for Progressive mRCC

October 23rd 2020

Sequencing After Frontline I/O Based Regimen for mRCC

October 23rd 2020

Clinical Trials for Relapsed/Refractory mRCC

October 23rd 2020

Upcoming Combination Trials for mRCC

October 23rd 2020

I/O Therapy After Progression on I/O for mRCC

October 23rd 2020

Role of TKI After Progression on I/O for mRCC

October 23rd 2020

Review of the COSMIC 021 Study for mRCC

October 23rd 2020

Introduction and Review of CheckMate 9ER for Metastatic RCC

October 23rd 2020

NABUCCO Trial Pursues Neoadjuvant Nivolumab/Ipilimumab in Advanced Urothelial Cancer

October 22nd 2020

The combination of preoperative nivolumab and ipilimumab demonstrated preliminary feasibility and safety in patients with locoregionally advanced urothelial cancer.